Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluation of MRI Measures of Lung Water With Posture Changes in Healthy Volunteers and in Patients With Cardiac Failure

29. maj 2014 opdateret af: GlaxoSmithKline

An Evaluation of MRI Measures of Lung Water Increases With Postural Changes in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure

The aim of this study is to establish a model for the evaluation of drug targets using postural measures to induce changes in lung water concentration as assessed by MRI. A reduction in the magnitude and rate of water transudation with postural changes in patients with congestive heart failure (CHF) could provide a model for the evaluation of various classes of molecules for target validation and for dose selection.

Studieoversigt

Status

Afsluttet

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

20

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Heart Failure Patients:
  • Established diagnosis of mild to moderate heart failure of any aetiology with symptoms defined as corresponding to the New York Heart Association (NYHA) class I, II or III
  • Able in the opinion of the patient and investigator to be supine for 1 hour and to experience passive leg raising (PLR) whilst in the MRI scanner
  • Male or female over 18 years of age at the time of signing the informed consent
  • Negative urine or serum pregnancy test
  • Capable of giving written informed consent
  • Registered with a UK general practitioner.
  • Participants must read (in English) at a level sufficient to adequately complete study related questionnaires
  • Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
  • Healthy Volunteers:
  • Healthy as determined by a responsible physician
  • Male or female over 18 years of age at the time of signing the informed consent
  • Capable of giving written informed consent
  • Negative urine or serum pregnancy test
  • Registered with a UK general practitioner
  • Participants must read (in English) at a level sufficient to adequately complete study related questionnaires
  • Able to understand and comply with protocol requirements, instructions and protocol-stated restrictions

Exclusion Criteria:

  • Heart Failure Patients
  • History of primary pulmonary disease requiring current medication or other therapy.
  • Orthopnoea of sufficient severity to preclude supine scanning.
  • Hip or leg pathology of sufficient severity to prevent extension of both legs to 45 degrees.
  • Unstable heart failure, defined as change in NYHA status, change in heart failure therapy regimen or hospitalization for acute decompensation of heart failure within preceding 6 weeks.
  • Unstable angina within the past 3 months
  • Current smoker, defined as having smoked in the preceding 1 year
  • Uncontrolled hypertension (resting systolic BP > 160 mmHg or resting diastolic BP > 100mmHg)
  • Resting hypoxia (SaO2 <93%).
  • Contraindication to MRI scanning
  • Pregnant females
  • Positive drugs of abuse or alcohol screen.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • Healthy Volunteers
  • History of primary pulmonary disease requiring current medication or other therapy
  • Current smoker, defined as having smoked in the preceding 1 year
  • Hip or leg pathology of sufficient severity to prevent extension of both legs to 45 degrees
  • Contraindication to MRI scanning
  • Pregnant females
  • Positive drugs of abuse or alcohol screen
  • Unwillingness or inability to follow the procedures outlined in the protocol

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Healthy Volunteer
Healthy Volunteer cohort
MRI of lungs to measure lung water content before and after passive leg raising (PLR)
Andet: Heart Failure
Heart Failure cohort
MRI of lungs to measure lung water content before and after passive leg raising (PLR)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Lung water distribution as measured by MRI
Tidsramme: Visit 1 and Visit 2 will be approximately 1 week apart
MRI test
Visit 1 and Visit 2 will be approximately 1 week apart
Lung water concentration as measured by MRI
Tidsramme: Visit 1 and Visit 2 will be approximately 1 week apart
MRI test
Visit 1 and Visit 2 will be approximately 1 week apart

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Between patient variability in lung water concentration as measured by MRI at 2 independent visits
Tidsramme: Visit 1 and Visit 2 will be approximately 1 week apart
MRI test
Visit 1 and Visit 2 will be approximately 1 week apart
Within patient variability in lung water concentration as measured by MRI at 2 independent visits
Tidsramme: Visit 1 and Visit 2 will be approximately 1 week apart
MRI test
Visit 1 and Visit 2 will be approximately 1 week apart

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. januar 2011

Primær færdiggørelse (Faktiske)

1. august 2011

Studieafslutning (Faktiske)

1. august 2011

Datoer for studieregistrering

Først indsendt

18. november 2010

Først indsendt, der opfyldte QC-kriterier

13. januar 2011

Først opslået (Skøn)

17. januar 2011

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

2. juni 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. maj 2014

Sidst verificeret

1. maj 2014

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 114747

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Hjertesvigt, kongestiv

Kliniske forsøg med MRI

Abonner